Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edesa BiotechEDSA +2.86%26 3-1 Month Momentum % is -57.36% as of Aug. 04, 2026. GuruFocus rates EDSA with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,393 Biotechnology companies, Edesa Biotech ranks worse than 96.77% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-04), Edesa Biotech's 3-1 Month Momentum % is -57.36%.
The industry rank for Edesa Biotech's 3-1 Month Momentum % or its related term are showing as below:
EDSA's 3-1 Month Momentum % is ranked worse than 96.77% of 1393
companies
in the Biotechnology industry
Industry Median: -6.97
vs EDSA: -57.36
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Edesa Biotech 3-1 Month Momentum % Related Terms
EDSA vs TCRX, DWTX, AURX: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Edesa Biotech's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edesa Biotech 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Edesa Biotech's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Edesa Biotech's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edesa Biotech (EDSA) has a 3-1 Month Momentum % of -57.36% as of Aug. 04, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Edesa Biotech and its competitors. According to the industry distribution chart, Edesa Biotech ranks #1348 out of 1393 companies in the Biotechnology industry, placing it in the top 96.8%.
Is Edesa Biotech's 3-1 Month Momentum % too high?
Edesa Biotech's current 3-1 Month Momentum % is -57.36%. Based on the distribution chart, Edesa Biotech ranks #1348 out of 1393 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Edesa Biotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Edesa Biotech's 3-1 Month Momentum % compare to TCRX and DWTX?
According to the Biotechnology industry distribution chart, Edesa Biotech ranks #1348 out of 1393 companies for 3-1 Month Momentum %. This places Edesa Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Edesa Biotech and its competitors. Edesa Biotech's current 3-1 Month Momentum % is -57.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edesa Biotech stock overvalued right now?
Edesa Biotech (EDSA) has a current 3-1 Month Momentum % of -57.36%. The current 3-1 Month Momentum % is -57.36%. Edesa Biotech's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Edesa Biotech (EDSA), the current 3-1 Month Momentum % is -57.36% as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
26GF Score
Get the complete analysis for EDSA
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDSA has been successfully added to your 
